Literature DB >> 2515524

The bioavailability of three altretamine formulations.

E A Runhaar1, J P Neijt, J J Holthuis, D de Vos.   

Abstract

The bioavailability of two altretamine preparations was studied in a randomized cross-over design. The two preparations were compared with a third in a parallel design. Dissolution differences between the preparations were observed, which could give rise to differences in bioavailability caused by the extensive first-pass effect of altretamine. The in vivo data showed a trend to differences in bioavailability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515524     DOI: 10.1007/bf01959414

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  21 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1984-02

3.  Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients.

Authors:  M D'Incalci; G Beggiolin; C Sessa; C Mangioni
Journal:  Eur J Cancer Clin Oncol       Date:  1981-12

4.  Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Toxicity of hexamethylmelamine (NSC-13875) in rats.

Authors:  T C Barnes; S Frances
Journal:  Arch Int Pharmacodyn Ther       Date:  1966-03

6.  Variable oral absorption of hexamethylmelamine in man.

Authors:  M D'Incalci; G Bolis; C Mangioni; L Morasca; S Garattini
Journal:  Cancer Treat Rep       Date:  1978-12

7.  Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.

Authors:  D Ross; S P Langdon; A Gescher; M F Stevens
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

8.  Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; S Garattini
Journal:  Cancer Treat Rep       Date:  1982-02

9.  The bioavailability of Tamoplex (tamoxifen). Part 2. A single dose cross-over study in healthy male volunteers.

Authors:  P J Guelen; D Stevenson; R J Briggs; D de Vos
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-10

10.  Determination of hexamethylmelamine and metabolites in plasma or serum by gas-liquid chromatography with a nitrogen-sensitive detector.

Authors:  A Hulshoff; J P Neijt; C F Smulders; A C van Loenen; H M Pinedo
Journal:  J Chromatogr       Date:  1980-03-14
View more
  2 in total

Review 1.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.